L-Carnitine (levocarnitine) is a naturally occurring quaternary ammonium compound that the body both synthesizes and obtains from food. It is one of the best-studied nutraceuticals in human nutrition, backed by hundreds of controlled trials, so this monograph treats it as an established dietary compound rather than an unproven research chemical. LC600 is a high-dose format of the same molecule, and all of the biochemistry and evidence below apply to L-carnitine as a substance.
Chemically it is (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate, molecular formula C7H15NO3, molar mass 161.20 g/mol. The L-isomer is the biologically active form; the D-isomer is not used by human enzymes and can interfere with L-carnitine handling.
Biochemistry and mechanism
The core job of carnitine is to move long-chain fatty acids across the inner mitochondrial membrane so they can be oxidized for energy. Long-chain acyl-CoA cannot cross that membrane on its own. Carnitine palmitoyltransferase 1 (CPT1) on the outer membrane transfers the acyl group onto carnitine to form acylcarnitine; carnitine-acylcarnitine translocase (CACT) carries it into the matrix; and CPT2 on the inner membrane hands the acyl group back to CoA for beta-oxidation. This carnitine shuttle is the rate-controlling gateway of fatty acid oxidation [1].
Carnitine has a second role as an acyl buffer. By accepting surplus acetyl groups it keeps the mitochondrial acetyl-CoA to free-CoA ratio in a workable range, which matters during intense metabolic flux. Acetyl-L-carnitine (ALC) is the acetylated ester that carries this pool and crosses the blood-brain barrier more readily, which is why ALC rather than plain L-carnitine appears in most neurological studies [1].
Sources, synthesis and pharmacokinetics
Humans synthesize carnitine from the amino acids lysine and methionine, mostly in liver and kidney, and reabsorb it efficiently in the kidney. Diet supplies the rest, with red meat the densest source and plant foods contributing little. Bioavailability differs sharply by source: dietary carnitine from a meal is 54–87% absorbed, while an oral supplement dose of roughly 0.5–6 g is absorbed largely by passive diffusion at only 14–18% [2]. Unabsorbed carnitine is fermented by bacteria in the large intestine [2].
The clinical importance of carnitine is clearest in its absence. Primary carnitine deficiency, caused by loss-of-function variants in the SLC22A5 gene encoding the OCTN2 transporter, produces very low plasma carnitine, cardiomyopathy, skeletal myopathy and hypoketotic hypoglycemia, and responds to lifelong carnitine supplementation [3]. This is a genuine human therapeutic indication, not an inference from animal data.
Human clinical evidence
Unlike most compounds catalogued here, L-carnitine has a large randomized human literature. The findings are mixed and effect sizes are usually modest, so they are summarized below with that caveat.
Body weight and composition
A meta-analysis of nine randomized trials (911 adults) found carnitine supplementation produced more weight loss than control (about 1.3 kg) and a small drop in BMI, with the effect shrinking over longer follow-up [6]. A larger synthesis of 37 randomized trials reached the same direction, reporting reductions in body weight, BMI and fat mass but no reliable change in waist circumference or body-fat percentage [7]. The practical reading is a small, real, but not dramatic effect.
Blood lipids and glycemic control
In adults with cardiovascular risk factors, a meta-analysis of randomized trials reported small reductions in total and LDL cholesterol and in fasting glucose, with high statistical heterogeneity that limits confidence [8].
Cardiovascular disease
A meta-analysis of 13 controlled trials (3,629 patients), largely in the setting of acute myocardial infarction, associated L-carnitine with lower all-cause mortality and fewer ventricular arrhythmias and angina episodes, though without a reduction in heart failure or reinfarction [4]. These trials are older and heterogeneous, so the signal is best read as hypothesis-generating rather than settled.
Exercise and muscle
A review of controlled work concluded that L-carnitine can lower markers of exercise-induced muscle damage and soreness and may support recovery, with a proposed mechanism of improved blood flow and reduced tissue hypoxia rather than a direct fat-burning effect [9].
Male fertility
In idiopathic male infertility, a network meta-analysis of randomized trials ranked L-carnitine among the more effective antioxidant options for improving sperm motility and morphology, while noting that effects on pregnancy rates remain uncertain and trial quality is variable [10].
Acetyl-L-carnitine in neurology
A Cochrane review of acetyl-L-carnitine for diabetic peripheral neuropathy found the evidence too low in quality to support a firm benefit and called for better trials [12]. A separate Cochrane review of ALC in hepatic encephalopathy likewise judged the evidence insufficient and of low certainty [11]. These honest null-to-uncertain reads matter as much as the positive ones.
Preclinical context
Much of the mechanistic detail, including the CPT shuttle model and the acyl-buffering role, was worked out in cell and animal systems and in inborn-error genetics [1]. Where this monograph cites animal or in-vitro work it says so; the weight, lipid, cardiovascular, fertility and neuropathy sections above are human randomized data.
Safety, tolerability and the TMAO question
Oral L-carnitine is generally well tolerated. The common complaints at gram-level doses are gastrointestinal (nausea, cramps, diarrhea) and, at high doses, a fishy body odor from trimethylamine. The most discussed concern is metabolic: gut bacteria convert a fraction of carnitine to trimethylamine, which the liver oxidizes to trimethylamine-N-oxide (TMAO), a metabolite associated in observational and mechanistic work with atherosclerosis [5]. The original study showed omnivores generate more TMAO from carnitine than vegetarians and that the pathway accelerated atherosclerosis in mice [5]. This is an active and unresolved area. It sits alongside the older human cardiac trials that reported benefit [4], and it does not by itself establish net harm in people. Absorption biology also blunts the exposure, since only a small fraction of a supplement dose is absorbed and much of the rest is fermented [2].
Dosing context
This section describes doses used in the published research, not a recommendation. Human trials most often used 1–3 g of L-carnitine per day, and acetyl-L-carnitine studies commonly used 1–3 g per day, usually split across the day and taken with food. Renal reabsorption saturates as blood levels rise, so a large single dose is cleared faster, and split dosing is the usual research practice [2].
Handling and storage
L-carnitine and its salts are hygroscopic. Keep the material in a closed container, away from moisture, heat and direct light, and follow the certificate of analysis for the specific lot. Weigh and reconstitute under clean conditions.
Research and educational context
This page is a neutral summary of published biochemistry and clinical research for informational and research use. It is not medical advice, a diagnosis, or a dosing recommendation, and nothing here replaces a qualified clinician. L-carnitine is well characterized in humans, but well studied is not the same as right for a given person, and the safety questions above are real.